Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corporativo FraguaB de CVCGSBF 84 Debt-to-EBITDA is 0.56 as of Dec. 2024, which is 19% above its 10-year median of 0.47. GuruFocus rates CGSBF with a GF Score™ of 84/100 and a GF Value™ of $43.12. Among 477 Healthcare Providers & Services companies, Corporativo FraguaB de CV ranks better than 80.71% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Corporativo FraguaB de CV's Debt-to-EBITDA or its related term are showing as below:
CGSBF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.34 Med: 0.47 Max: 0.6
Current: 0.56
During the past 13 years, the highest Debt-to-EBITDA Ratio of Corporativo FraguaB de CV was 0.60. The lowest was 0.34. And the median was 0.47.
CGSBF's Debt-to-EBITDA is ranked better than 80.71% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs CGSBF: 0.56
Corporativo FraguaB de CV (OTCPK:CGSBF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Corporativo FraguaB de CV Debt-to-EBITDA Related Terms
Corporativo FraguaB de CV Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corporativo FraguaB de CV Debt-to-EBITDA Competitor Comparison
For the Pharmaceutical Retailers subindustry, Corporativo FraguaB de CV's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corporativo FraguaB de CV Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Corporativo FraguaB de CV's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Corporativo FraguaB de CV's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (Dec. 2024) EBITDA data.
Corporativo FraguaB de CV (CGSBF) has a Debt-to-EBITDA of 0.56 as of Dec. 2024. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Corporativo FraguaB de CV. This is 19% above median its historical median of 0.47. Over the past decade, Corporativo FraguaB de CV's Debt-to-EBITDA has ranged from 0.34 to 0.60. According to the industry distribution chart, Corporativo FraguaB de CV ranks #92 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 19.3%.
Is Corporativo FraguaB de CV's Debt-to-EBITDA too high?
Corporativo FraguaB de CV's current Debt-to-EBITDA of 0.56 is 19% above median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 0.60. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. Corporativo FraguaB de CV's value of 0.56 is 74.8% below this industry median. Based on the distribution chart, Corporativo FraguaB de CV ranks #92 out of 477 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Corporativo FraguaB de CV has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Corporativo FraguaB de CV's Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Corporativo FraguaB de CV ranks #92 out of 477 companies for Debt-to-EBITDA. This places Corporativo FraguaB de CV in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.22. Corporativo FraguaB de CV's value of 0.56 is 74.8% below this benchmark. Historically, Corporativo FraguaB de CV's own Debt-to-EBITDA has ranged from 0.34 to 0.60 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 2.22, Corporativo FraguaB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corporativo FraguaB de CV's current Debt-to-EBITDA of 0.56 is 74.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Corporativo FraguaB de CV. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corporativo FraguaB de CV's current Debt-to-EBITDA is 0.56, which is 19% above median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corporativo FraguaB de CV stock overvalued right now?
Corporativo FraguaB de CV (CGSBF) has a current Debt-to-EBITDA of 0.56. The stock's GF Value™ is $43.12, compared to a current price of $29.66 — trading 31.2% below its estimated fair value. The current Debt-to-EBITDA is 0.56, which is 19% above median its 10-year median of 0.47 and 74.8% below the Healthcare Providers & Services industry median of 2.22. Corporativo FraguaB de CV's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Corporativo FraguaB de CV (CGSBF), the current Debt-to-EBITDA is 0.56 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corporativo FraguaB de CV (CGSBF) Overvalued in 2026?
Based on GuruFocus' analysis, Corporativo FraguaB de CV stock appears to be undervalued.
The current stock price of $29.66 is trading 31.2% below its estimated GF Value™ of $43.12.
Key valuation signals for CGSBF:
Debt-to-EBITDA: 0.56 (19% above median its 10-year median of 0.47)
GF Value™: $43.12 vs. price of $29.66 (31.2% below fair value)
Industry Position: 74.8% below the Healthcare Providers & Services median (#92 of 477)
No single metric tells the full story. See the CGSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corporativo Fragua SAB de CV is engaged in the drug retail sector in Mexico. The company operates a network of pharmacies under the SuperFarmacia brand name, focusing on selling medicines, medical devices, and a variety of other products, including grocery items, exercise machines, perfumes, housewares, electronics, personal care products, toys, and photographic equipment.
84GF Score
Get the complete analysis for CGSBF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGSBF has been successfully added to your 
